Boots and Superdrug – Toxins & Fillers - Why were they not Successful?

Following my review of the history and financial journeys of some of the biggest aesthetic groups in the industry — including sk:n, Therapie, Transform, and The Private Clinic — as well as a look at the global toxin and filler market, the next video in this series (under three minutes) shifts focus to Boots and Superdrug’s ventures into the cosmetic injectables space.

Back in the late '90s and early 2000s, during my time at Allergan managing what was then the unlicensed Botox Cosmetic business, I had many memorable experiences. One that really stands out was being approached by Boots — the UK’s largest and most recognised high street pharmacy chain, with over 1,800 outlets — to help them launch a Botox service.

In this video, I’ll explore some of the reasons why both Boots and Superdrug (with 755 stores) have failed to truly tap into the explosive growth of this market — and highlight a key lesson smaller clinic owners can take away from their attempts.

Click the link to watch the video: Boots and Superdrug High Street Pharmacies – Why were they not Successful with Toxins and Fillers?